Comprehensive assessment of tigecycline activity tested against a worldwide collection of Acinetobacter spp. (2005-2009)

被引：43
作者：
Mendes, Rodrigo E. [1 ]
Farrell, David J. [1 ]
Sader, Helio S. [1 ]
Jones, Ronald N. [1 ,2 ]
机构：
[1] JMI Labs, N Liberty, IA 52317 USA
[2] Tufts Univ, Sch Med, Boston, MA 02111 USA
来源：
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE | 2010年 / 68卷 / 03期
关键词：
Tigecycline; Acinetobacter spp; Multidrug resistance; Nosocomial infections; EXPERIENCE; BAUMANNII;
D O I：
10.1016/j.diagmicrobio.2010.07.003
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
A total of 5127 Acinetobacter spp. were collected from 140 hospitals in 32 countries in North America (17.1%), Europe (22.9%), Latin America (25.2%), and the Asia-Pacific (APAC) region (34.8%). Tigecycline MIC distributions were bimodal against isolates from North America and APAC region, while a unimodal pattern was noted for strains from Latin America. A variable MIC distribution was noted in Europe. Only tigecycline (MIC50/90, 0.5/2 mu g/mL) and polymyxin B (MIC50/90, 0.5/1 mu g/mL; 98.6% susceptible) exhibited high activity against Acinetobacter spp. Overall, tigecycline inhibited at least 90.0% of Acinetobacter spp. isolates from all countries evaluated at <= 2 mu g/mL, as well as 95.0% of those displaying multidrug resistance. Other tested agents showed limited activity and a significant (P < 0.001) trend toward decreased susceptibility during the study period. (C) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码：307 / 311
页数：5
相关论文
共 19 条
[11]  
Livermore DM, 2008, J ANTIMICROB CHEMOTH, V62, pII41, DOI [10.1093/jac/dkn351, 10.1093/jac/dkn371]
[12]   Has the era of untreatable infections arrived? [J].
Livermore, David M. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 64 (04) :29-36
[13]   Clonal dissemination of two clusters of Acinetobacter baumannii producing OXA-23 or OXA-58 in Rome, Italy [J].
Mendes, R. E. ;
Spanu, T. ;
Deshpande, L. ;
Castanheira, M. ;
Jones, R. N. ;
Fadda, G. .
CLINICAL MICROBIOLOGY AND INFECTION, 2009, 15 (06) :588-592
[14]   Codetection of blaOXA-23-Like Gene (blaOXA-133) and blaOXA-58 in Acinetobacter radioresistens: Report from the SENTRY Antimicrobial Surveillance Program [J].
Mendes, Rodrigo E. ;
Bell, Jan M. ;
Turnidge, John D. ;
Castanheira, Mariana ;
Deshpande, Lalitagauri M. ;
Jones, Ronald N. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (02) :843-844
[15]   Clinical Experience with Tigecycline in the Treatment of Carbapenem-Resistant Acinetobacter Infections [J].
Metan, G. ;
Alp, E. ;
Yildiz, O. ;
Percin, D. ;
Aygen, B. ;
Sumerkan, B. .
JOURNAL OF CHEMOTHERAPY, 2010, 22 (02) :110-114
[16]   Global challenge of multidrug-resistant Acinetobacter baumannii [J].
Perez, Federico ;
Hujer, Andrea M. ;
Hujer, Kristine M. ;
Decker, Brooke K. ;
Rather, Philip N. ;
Bonomo, Robert A. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (10) :3471-3484
[17]   Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit [J].
Sader, HS ;
Jones, RN ;
Dowzicky, MJ ;
Fritsche, TR .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2005, 52 (03) :203-208
[18]   Epidemiology, medical outcomes and costs of catheter-related bloodstream infections in intensive care units of four European countries: literature- and registry-based estimates [J].
Tacconelli, E. ;
Smith, G. ;
Hieke, K. ;
Lafuma, A. ;
Bastide, P. .
JOURNAL OF HOSPITAL INFECTION, 2009, 72 (02) :97-103
[19]   Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study [J].
Wisplinghoff, H ;
Bischoff, T ;
Tallent, SM ;
Seifert, H ;
Wenzel, RP ;
Edmond, MB .
CLINICAL INFECTIOUS DISEASES, 2004, 39 (03) :309-317
12